tbuckley/cabot-search huggingface dataset:
Perspectives on the physician workforce to the year 2020
Authors: R. A. Cooper
Journal: JAMA (1995)

Physician supply and demand for the period extending to 2020 were assessed from three perspectives: physician utilization in group- and staff-model health maintenance organizations, physician distribution, and the future supply of nonphysician clinicians. The national norm for physician demand in 1993 was estimated to be 205 per 100000 population. Demand is projected to increase 18% by 2020, because of both an expansion in beneficial services and a reduction in physician work effort. Supply initially will increase more rapidly, resulting in a surplus of 31 000 physicians (5% of patient care physicians) in the year 2000 and increasing to 62 000 physicians (8%) in 2010, after which the gap will narrow. Similar results were obtained when previous studies that had projected surpluses of 73 000 to 165 000 physicians (15% to 30%) in the year 2000 were reevaluated. However, physician distribution is not homogeneous, and the number of physicians per capita currently varies by more than twofold among states. Relative to the national norm, surpluses already exist in some states and shortages in others. In addition, the supply of nonphysician clinicians with independent practice authority is increasing. Their numbers are projected to double by 2010, equaling 60% of the number of patient care physicians. Measured as physician equivalents, their growth will equal the growth in physician supply. Thus, in terms of physicians alone, there is no evidence of a major impending national surplus. Local surpluses will be influenced principally by how physicians distribute themselves geographically. The major determinant of overall physician surpluses in the future will be the extent to which patients continue to seek physicians for services that also will be offered by an expanded work-force of nonphysician clinicians. Policy is needed that encompasses the universe of clinicians who will be providing care to patients in the next century. (<i>JAMA</i>. 1995;274:1534-1543)
"Schizoid"
Authors: Robert S. Palmer
Journal: JAMA (1973)

<h3>To the Editor.—</h3> Dr. Lyons (225:313, 1973) chides Dr. N. J. C. Andreasen's psychiatric aspersions on James Joyce as "schizoid" (224:67,1973). All art is a projection of the artist's mind on reality, as many years ago averred by My Lord Clark, then plain Mr. Clark, to the Harvard boys in a lecture "Icon and Idea"; ditto modern myth makers, eg, Freud and Jung. A touch of "psychosis" may be quite all right in ourselves as physicians in our roles as hired listening posts. Declared and accepted by us, our patients, and our friends, and not acted out so as to repel them or attract the unfavorable attention of the police, it is an immunization of our psyches. Joyce, as God's priest, transubstantiated the banal day in Dublin so that we faithful may partake of the body and blood of eternal mother nature. Thomas Pynchon (<i>Gravity's Rainbow</i>, Viking Press, 1973) declares
Medical education and American students at Guadalajara and Bologna
Authors: G. H. Hunt
Journal: JAMA (1971)

Before I discuss the American students at Guadalajara and Bologna, it may be well to present some background information, so that the question may be seen in perspective. First, as to numbers, according to a recent estimate,<sup>1</sup>the total number of American citizens studying medicine abroad is probably in the range of 3,500 to 4,000. The number of students finishing the medical course abroad and taking the Educational Council for Foreign Medical Graduates examination, however, is smaller than these figures would suggest. During the three calendar years 1968 through 1970, in six ECFMG examinations, a total of 2,103 examinations were administered to US citizens, an average of about 350 in each examination are repeaters. Of this whole group, a total of 737 American citizens passed the examination, an average of 123 for each examination, or 246 each year. During these three years a total of 72,096 examinations were administered
From the NIH: Variation in taste thresholds with human aging
Journal: JAMA (1982)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Beiträge zur Röntgendiagnostik der Otitis media acuta und ihrer Komplikationen in Schläfenbein
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Is Everybody Happy?
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Septic Bursitis
Authors: JAMES A. ENGELBRECHT
Journal: Annals of Internal Medicine (1978)

Letters and Correction1 December 1978Septic BursitisJAMES A. ENGELBRECHT, M.D., MARK MUELLER, M.D.JAMES A. ENGELBRECHT, M.D.Search for more papers by this author, MARK MUELLER, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-89-6-1011_3 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: We have read with interest the article on septic bursitis (Ann Intern Med 89:21-27, 1978). Previous anecdotal reports indicated a low incidence of septic bursitis, and most current textbooks reflect this "dogma." Our recent experience suggests a surprisingly high incidence of infected bursae in patients presenting with acute bursitis.In the past 2 months we have seen two patients with bursitis (one with prepatellar and one with bilateral olecranon) from whichStaphylococcus aureuswas cultured. Each case involved trauma to the area but no evidence of skin breakage or fracture. Interestingly, the prepatellar bursitis occurred in a... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: JAMES A. ENGELBRECHT, M.D.; MARK MUELLER, M.D.Affiliations: Veterans Administration Hospital Salt Lake City, UT 84148 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited bySeptic olecranon bursitis, contact dermatitis, and pneumonitis in a gas turbine engine mechanicOlecranon and pretibial bursitis in atopic dermatitis: Coincidence or association?Predisposing Factors, Bacteriology and Antibiotic Therapy in 35 Cases of Septic Bursitis 1 December 1978Volume 89, Issue 6Page: 1011-1011KeywordsStaphylococcus aureus ePublished: 1 December 2008 Issue Published: 1 December 1978 PDF downloadLoading ...
THE PHYSIOLOGY OF CARDIAC MUSCLE
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Neoplastic and Nonneoplastic Hepatic Changes in Lake Whitefish (Coregonus clupeaformis) from the St. Lawrence River, Quebec, Canada
Authors: Igor Mikaelian, Yves de Lafontaine, Chantal Menard, Pierre Tellier, John C. Harshbarger, Daniel Martineau
Journal: Environmental Health Perspectives (1998)

As part of a survey of fish diseases, lake whitefish (Coregonus clupeaformis) were collected in fall 1995 from the St. Lawrence River 15 km upstream of Quebec City, Quebec, Canada, to assess the prevalence of liver lesions. A total of 141 fish were captured and necropsied, and three standard sections of liver were taken for histological examination. Prevalences of altered hepatocyte foci, hepatocellular carcinoma, cholangioma, and cholangiocarcinoma were 0.7%, 2.1%, 0.7%, and 2.1%, respectively. Thus, the overall prevalence of liver neoplasia was 4.9% (7/141). Hepatic tumors were only observed in fish 7 years old or older. Fish age was significantly and positively correlated with the index assessing the number and size of macrophage aggregates (p<0.001; rs = 0.16). Hepatocyte vacuolation, anisokaryosis, lymphocytic infiltration, and bile duct hyperplasia were also observed but were not related to the age, length, sex, or condition factor of the fish. These results represent the first report on a series of hepatic tumors in a wild salmonid species.
DEALING WITH A MISS DEPLOYED OESOPHAGEAL STENT PLACED FOR VARICEAL BLEEDING
Authors: R Küttner-Magalhães, E Rodrigues-Pinto, M Lemos-Rocha, E Dias, C Pinto, J Silva, JM Ferreira, I Pedroto
Journal: Endoscopy (2020)

A 54-year-old male, with Child-Pugh C cirrhosis underwent band ligation of large oesophageal varices due to beta blockers intolerance. Four ligation-induced ulcer bleeding episodes occurred and a fully covered SX-Ella Danis metal stent was placed. On endoscopic evaluation, stent distal end was proximal to oesophago-gastric junction with major bleeding occurring in the distal, non-covered oesophagus. After sclerosant injection, bleeding flow diminished. The retrieval stent loop was grasped, allowing slight constriction and distal placement of the stent, with adequate coverage of distal oesophagus and bleeding control. Stent was later removed after transjugular intrahepatic portosystemic shunt.
<i>Announcement: </i>Implementation of the Vaccine Adverse Event Reporting System 2.0 Reporting Form
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

The Vaccine Adverse Event Reporting System (VAERS), co-managed by CDC and the Food and Drug Administration (FDA), is the national postmarketing safety monitoring system that accepts reports about adverse events that occur after administration of U.S.-licensed vaccines (1,2). On June 30, 2017, CDC and FDA implemented a revised reporting form and a new process for submitting reports to VAERS. Persons reporting adverse events are now able to use the VAERS 2.0 online reporting tool to submit reports directly online; alternatively, they may download and complete the writable and savable VAERS 2.0 form and submit it using an electronic document upload feature.
Part of Text Omitted, Aug 24 Issue
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LUXEMBOURG
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3594: GLUT1 as a metabolic target in glioblastoma therapy
Authors: Collin M. Labak, Maheedhara R. Guda, Neha Jain, Chase P. Smith, Charles P. Cain, Andrew J. Tsung, Kiran K. Velpula
Journal: Cancer Research (2019)

Abstract Glioblastoma (GBM) is an aggressive diffuse glioma with poor prognosis due to lack of sound therapeutic options. As in many aggressive tumors, GBMs create a hypoxic microenvironment and switch to glycolytic metabolism from oxidative phosphorylation in what is known as the Warburg Effect. Here, we hypothesize that strategically inhibiting influx of glucose via targeting GLUT1 may reverse the Warburg Effect and selectively slow tumor progression. Nanostring data suggests an aberrant metabolic clincial profile in our cohort of GBM patients. Datamining studies and immunoblot analysis were conducted on these same human GBM specimens to demonstrate upregulated GLUT1. Mass spectrometric analysis was performed on GLUT1 precipitated from mesenchymal subtype patient-derived xenograft (PDX). Zonula Occludens adhesion studies were carried out to determine GLUT1 inhibition's effects on cell-cell adhesion structures. Finally, ATP, lactate release, and glucose uptake assays were performed on PDX and GLUT1-silenced PDX to demonstrate a normalized metabolic phenotype when GLUT1 is silenced. Our work suggests that GLUT1 overexpression plays a major role in the metabolic profile of mesenchymal subtype GBM, and that targeting its overexpression could prove effective in reversing the Warburg Effect in GBM cells and ultimately improving patient outcomes. Citation Format: Collin M. Labak, Maheedhara R. Guda, Neha Jain, Chase P. Smith, Charles P. Cain, Andrew J. Tsung, Kiran K. Velpula. GLUT1 as a metabolic target in glioblastoma therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3594.
Nantucket fever. An additional case of babesiosis
Authors: W. B. Scharfman
Journal: JAMA (1977)

BABESIOSIS, formerly a rarity in humans, can no longer be considered unusual. It now appears that this is a ubiquitous disorder that has been described as occurring on Nantucket Island, Martha's Vineyard, Shelter Island off the eastern coast of Long Island, and Montauk Point, the easternmost tip of Long Island. A recent editorial<sup>1</sup>drew attention to this heretofore unusual infection, and the diagnosis in our patient was suggested by this description. The clinical spectrum of the disease suggests malaria. It is characterized by fever, marked lethargy and malaise, myalgia, and occasionally dark urine. Importantly, the hematologic studies show a hemolytic anemia of a nonimmune variety; leukopenia is present. Additionally, it is quite common for the results of liver function studies to be abnormal. <h3>Report of a Case</h3> A 53-year-old housewife who had vacationed on Nantucket Island since the middle of June was seen on Aug 20, 1976, because of fever,
THE CHICAGO SESSION
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Analysis of an observational registry of gastrointestinal stromal tumor (GIST) patients (pts) in the USA: reGISTry
Authors: C. D. Blanke, P. W. Pisters, J. C. Trent, M. von Mehren, J. Picus, E. Stealey, D. Williams
Journal: Journal of Clinical Oncology (2008)

21502 Background: The reGISTry, an observational, internet-based database initiated in November 2004, was designed to characterize evolving community and university-delivered patterns of care for non-study pts with GIST. Methods: After pts with confirmed GIST provide informed consent, physicians enter data that includes pt demographics, clinical characteristics, outcomes and therapy provided for GIST. Analyses are performed every 6 months. reGISTry data from unique sites are compared to the aggregate pool, to provide feedback to individual investigators. Results: As of Oct 2007, there were 628 pts enrolled from 113 centers; 342 pts (54%) came from community practices. At diagnosis, 513 pts (82%) had a localized tumor, 592 pts (94%) had KIT testing, and 3% had genotyping. 519 pts (83%) had surgery as first-line treatment, including 89% of pts with localized and 57% with metastatic disease. 9% and 40% of pts with localized and metastatic disease respectively had systemic therapy as initial treatment. Of pts who received any systemic therapy, 339 pts (54%) were treated with imatinib mesylate; 76% starting at 400mg daily, and 56 pts (9%) were treated with sunitinib malate; 84% starting at 50mg. Where appropriate, therapeutic efficacy was assessed by tumor size on CT (74%), tumor size and radiodensity on CT (29%), and PET (9%). In the adjuvant setting 103 pts received imatinib. Of the 43 pts (42%) currently receiving adjuvant imatinib and the 60 pts (58%) who discontinued, the median duration of therapy was 102 days and 366 days respectively. For all pts that received imatinib and sunitinib, 12% and 16% had subsequent surgery with a median time till surgery of 173 days and 123 days respectively. Conclusions: The reGISTry is a useful tool for determining evolving management patterns in GIST and points out differences from official guidelines. KIT testing is common in the community, but genotyping is rare. Assessment by CT is common but rare by PET. The starting dose of imatinib and sunitinib remains 400mg and 50mg respectively for the majority of pts. The median duration of adjuvant imatinib is approximately one year. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Novartis Novartis Novartis